Search
Delandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigationalIt was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). … [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein.
Trimebutine
go.drugbank.com/drugs/DB09089ApprovedInvestigationalTrimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries. … It is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form.
Osseous Paget's Disease
go.drugbank.com/conditions/DBCOND0069879Synonyms: Paget Disease of Bone, Paget's Disease of BoneOuabain
go.drugbank.com/drugs/DB01092ApprovedIt is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.
Categories: Compounds used in a research, industrial, or household settingSecretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalPurified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S.. … The hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 [L1875].
Daraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigational[L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common … [L64039,L64040] It is the first targeted cancer medicine approved from the class of RAS(ON) multi-selective and mutant-selective inhibitors.[L64041]
Lifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigational] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma. … Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341
Vecuronium
go.drugbank.com/drugs/DB01339ApprovedInvestigationalIts lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or … A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium.
Calcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalIt is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients.
Categories: Bone Density Conservation AgentsAcetohexamide
go.drugbank.com/drugs/DB00414ApprovedWithdrawnA sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Categories: Drugs Used in DiabetesSynonyms: N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea, 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide